Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
SNTI Stock Forecast 2025-2026
$2.28
Current Price
$74.43M
Market Cap
Buy 2
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to SNTI Price Targets
+557.9%
To High Target of $15.00
+492.1%
To Median Target of $13.50
+426.3%
To Low Target of $12.00
SNTI Price Momentum
-20.3%
1 Week Change
-29.6%
1 Month Change
-7.7%
1 Year Change
-35.0%
Year-to-Date Change
-86.5%
From 52W High of $16.94
+50.0%
From 52W Low of $1.52
📊 TOP ANALYST CALLS
Did SNTI Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Senti Biosciences is one of their latest high-conviction picks.
Latest SNTI Stock Price Targets & Analyst Predictions
Based on our analysis of 5 Wall Street analysts, SNTI has a bullish consensus with a median price target of $13.50 (ranging from $12.00 to $15.00). The overall analyst rating is Strong Buy (9.0/10). Currently trading at $2.28, the median forecast implies a 492.1% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Yale Jen at Laidlaw & Co., projecting a 557.9% upside. Conversely, the most conservative target is provided by Geulah Livshits at Chardan Capital, suggesting a 426.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SNTI Analyst Ratings
2
Buy
0
Hold
0
Sell
SNTI Price Target Range
Low
$12.00
Average
$13.50
High
$15.00
Current: $2.28
Latest SNTI Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SNTI.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 12, 2025 | Chardan Capital | Geulah Livshits | Buy | Maintains | $12.00 |
| Jun 6, 2025 | Laidlaw & Co. | Yale Jen | Buy | Initiates | $15.00 |
| May 2, 2025 | Chardan Capital | Geulah Livshits | Buy | Maintains | $12.00 |
| Dec 4, 2024 | Chardan Capital | Geulah Livshits | Buy | Maintains | $12.00 |
| Dec 2, 2024 | Chardan Capital | Geulah Livshits | Buy | Maintains | $10.00 |
| Aug 15, 2023 | Chardan Capital | Geulah Livshits | Buy | Reiterates | $6.00 |
| May 11, 2023 | Chardan Capital | Geulah Livshits | Buy | Maintains | $6.00 |
| Mar 24, 2023 | Morgan Stanley | Michael Ulz | Equal-Weight | Maintains | $2.00 |
| Mar 23, 2023 | Chardan Capital | Geulah Livshits | Buy | Maintains | $7.00 |
| Jan 30, 2023 | Chardan Capital | Geulah Livshits | Buy | Maintains | $8.00 |
| Jan 27, 2023 | Morgan Stanley | Michael Ulz | Equal-Weight | Maintains | $3.00 |
| Dec 16, 2022 | JP Morgan | Brian Cheng | Neutral | Initiates | $0.00 |
| Oct 7, 2022 | Morgan Stanley | Michael Ulz | Equal-Weight | Initiates | $7.50 |
| Sep 29, 2022 | B of A Securities | Greg Harrison | Buy | Initiates | $7.00 |
| Sep 23, 2022 | Chardan Capital | Geulah Livshits | Buy | Initiates | $12.00 |
Senti Biosciences Inc. (SNTI) Competitors
The following stocks are similar to Senti Biosciences based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
SNTI
Senti Biosciences
mkt cap
74.59M
Senti Biosciences Inc. (SNTI) Financial Data
Senti Biosciences Inc. has a market capitalization of $74.43M with a P/E ratio of 7.7x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -116.6%.
Valuation Metrics
Market Cap
$74.43M
Enterprise Value
$73.16M
P/E Ratio
7.7x
PEG Ratio
-3.8x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+57.0%
Current Ratio
4.2x
Debt/Equity
85.7x
ROE
-116.6%
ROA
-36.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Senti Biosciences Inc. (SNTI) Business Model
About Senti Biosciences Inc.
What They Do
Develops next-generation cell and gene therapies.
Business Model
Senti Biosciences Inc. generates revenue by creating innovative therapies leveraging synthetic biology to address complex diseases, especially in oncology. Their business model revolves around engineering genetic circuits that enhance the precision and effectiveness of treatments, aiming to revolutionize patient care and outcomes.
Additional Information
The company is dedicated to advancing the biomedical field by focusing on customizable and intelligent therapeutics. Their commitment to enhancing treatment paradigms positions them as a significant player in the healthcare sector, with a potential to impact various therapeutic areas.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
34
CEO
Dr. Timothy K. Lu M.D., Ph.D.
Country
United States
IPO Year
2021
Website
www.sentibio.comSenti Biosciences Inc. (SNTI) Latest News & Analysis
Latest News
Quick Summary
Senti Biosciences has made progress in its Phase 1 trial of SENTI-202 for Acute Myeloid Leukemia. The FDA granted Orphan Drug Designation for this treatment targeting relapsed/refractory cases.
Why It Matters
Progress in SENTI-202's clinical trial and FDA's Orphan Drug Designation highlight potential for Senti Bio to address a significant market need in AML, impacting stock value and investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Senti Biosciences granted stock options for 102,500 shares at $3.03 each to eight new employees under its 2022 Inducement Equity Plan on June 3, 2025.
Why It Matters
The stock options granted indicate management's confidence in future growth, potentially aligning employee interests with shareholder value and affecting stock performance positively.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Pomerantz LLP is investigating claims for Senti Biosciences, Inc. (NASDAQ: SNTI) investors. Interested parties can contact Danielle Peyton for more information.
Why It Matters
The investigation into Senti Biosciences could indicate potential legal issues or financial mismanagement, impacting investor confidence and stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Senti Bio to Participate in a Virtual Fireside Chat Hosted by Chardan Capital Markets, LLC
13 days ago
Quick Summary
Senti will host a moderated webcast fireside chat with its management and Chardan analyst Geulah Livshits on June 9th at 3:00 PM ET.
Why It Matters
The webcast indicates upcoming insights from Senti management and a reputable analyst, potentially affecting stock valuation and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for investors who purchased Senti Biosciences, Inc. (NASDAQ:SNTI). More information is available at bgandg.com/SNTI.
Why It Matters
The investigation into Senti Biosciences may indicate potential legal issues or financial irregularities, impacting stock performance and investor confidence in the company.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Levi & Korsinsky, LLP is investigating Senti Biosciences Inc (NASDAQ:SNTI) regarding the fairness of its acquisition and potential harm to stockholders prior to June 1, 2022.
Why It Matters
The investigation into Senti Biosciences' acquisition may indicate potential legal issues and governance concerns, impacting investor confidence and stock value.
Source: Accesswire
Market Sentiment:
Neutral
Frequently Asked Questions About SNTI Stock
What is Senti Biosciences Inc.'s (SNTI) stock forecast for 2025?
Based on our analysis of 5 Wall Street analysts, Senti Biosciences Inc. (SNTI) has a median price target of $13.50. The highest price target is $15.00 and the lowest is $12.00.
Is SNTI stock a good investment in 2025?
According to current analyst ratings, SNTI has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.28. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SNTI stock?
Wall Street analysts predict SNTI stock could reach $13.50 in the next 12 months. This represents a 492.1% increase from the current price of $2.28. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Senti Biosciences Inc.'s business model?
Senti Biosciences Inc. generates revenue by creating innovative therapies leveraging synthetic biology to address complex diseases, especially in oncology. Their business model revolves around engineering genetic circuits that enhance the precision and effectiveness of treatments, aiming to revolutionize patient care and outcomes.
What is the highest forecasted price for SNTI Senti Biosciences Inc.?
The highest price target for SNTI is $15.00 from Yale Jen at Laidlaw & Co., which represents a 557.9% increase from the current price of $2.28.
What is the lowest forecasted price for SNTI Senti Biosciences Inc.?
The lowest price target for SNTI is $12.00 from Geulah Livshits at Chardan Capital, which represents a 426.3% increase from the current price of $2.28.
What is the overall SNTI consensus from analysts for Senti Biosciences Inc.?
The overall analyst consensus for SNTI is bullish. Out of 5 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $13.50.
How accurate are SNTI stock price projections?
Stock price projections, including those for Senti Biosciences Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 19, 2025 11:58 AM UTC